[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355233-105":59,"doc-detail-355233-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","clonal-haematopoiesis-in-chronic-lymphocytic-leukaemia-biology-inflammaging-and-clinical-implications-in-the-era-of-targeted-therapy","Clonal haematopoiesis in chronic lymphocytic leukaemia - Biology, inflammaging and clinical implications in the era of targeted therapy","","Clonal haematopoiesis (CH) is an age-related condition increasingly relevant to haematologic malignancies, with growing focus on its prevalence and clinical implications in chronic lymphocytic leukaemia (CLL). This review synthesizes evidence on CH’s biological basis, epidemiology, and clinical impact, linking CH with genomic instability, immune dysregulation, and inflammaging. It evaluates CH–therapy interactions, particularly with BTK and BCL2 inhibitors, and summarizes effects on prognosis, toxicities, cardiovascular risk, and therapy-related myeloid neoplasms. Future work is needed to clarify Richter transformation risk and enable routine CH assessment.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clonal-haematopoiesis-in-chronic-lymphocytic-leukaemia-biology-inflammaging-and-clinical-implications-in-the-era-of-targeted-therapy/355233/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clonal-haematopoiesis-in-chronic-lymphocytic-leukaemia-biology-inflammaging-and-clinical-implications-in-the-era-of-targeted-therapy/355233.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is clonal haematopoiesis and why is it important in chronic lymphocytic leukaemia?","Question",{"text":112,"@type":113},"Clonal haematopoiesis (CH) is an age-related condition that becomes increasingly recognized in haematologic malignancies. In CLL, CH prevalence and clinical implications are gaining attention because it may affect disease biology and patient outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does CH relate to inflammaging and immune dysregulation in CLL?",{"text":117,"@type":113},"The review connects CH with genomic instability, chronic inflammation, and immune system alterations. CH is discussed as interacting with inflammaging and immune dysregulation, which can shape CLL progression and clinical risk.",{"name":119,"@type":110,"acceptedAnswer":120},"What role might CH play in targeted therapy outcomes and adverse events?",{"text":121,"@type":113},"Available evidence suggests CH can influence prognosis and treatment-related toxicities, including cardiovascular risk. The review highlights that targeted therapies such as BTK and BCL2 inhibitors may interact differently with CH than chemoimmunotherapy, potentially modifying long-term outcomes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355233,1790198268,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","DOI: 10.1002/ctm2.70633  \nREVIEW  \nClonal haematopoiesis in chronic lymphocytic leukaemia: Biology, inflammaging and clinical implications in the era of targeted therapy  \nEnrica Antonia Martino1  Santino Caserta1  Mamdouh Skafi2 Maria Eugenia Alvaro1  Antonella Bruzzese1  Nicola Amodio3 Virginia Olivito1  Caterina Labanca1  Francesco Mendicino1   \nEugenio Lucia1 Ernesto Vigna1  \nFortunato Morabito4  Massimo Gentile1, 5   \n1Unit of Hematology, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy  \n2 Department of Emergency and Internal Medicine, Saint Joseph Hospital, East Jerusalem, Palestine  \n3 Department of Experimental and Clinical Medicine, University of Catanzaro, Catanzaro, Italy  \n4AIL Sezione di Cosenza, Cosenza, Italy  \n5 Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy  \nCorrespondence  \nMassimo Gentile, Unit of Hematology, Department of Onco-Hematology, AO of Cosenza, viale della Repubblica snc, Cosenza 87100, Italy. [Email:](Email: massimo.gentile@unical.it)[ massimo.gentile@unical.it](Email: massimo.gentile@unical.it)  \nGraphical Abstract  \nIn an ageing and inflamed haematopoietic ecosystem, clonal haematopoiesisand chronic lymphocytic leukaemia may originate from shared or parallel stem cell clones. This interaction modulates the effects of targeted therapies and contributes to cytopenias, cardiovascular toxicity, therapy-related myeloid neoplasms and Richter transformation.  \nClin. Transl. Med. 2026;16:e70633 .  \n[https://doi.org/10.1002/ctm2.70633](https://doi.org/10.1002/ctm2.70633)  \n[wileyonlinelibrary.com/journal/ctm2](wileyonlinelibrary.com/journal/ctm2)  \nDOI: 10.1002/ctm2.70633  \nREVIEW  \nClonal haematopoiesis in chronic lymphocytic leukaemia: Biology, inflammaging and clinical implications in the era of targeted therapy  \nEnrica Antonia Martino1  Santino Caserta1  Mamdouh Skafi2 Maria Eugenia Alvaro1  Antonella Bruzzese1  Nicola Amodio3 Virginia Olivito1  Caterina Labanca1  Francesco Mendicino1   \nEugenio Lucia1 Ernesto Vigna1  \nFortunato Morabito4  Massimo Gentile1, 5   \n1Unit of Hematology, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy  \n2 Department of Emergency and Internal Medicine, Saint Joseph Hospital, East Jerusalem, Palestine  \n3 Department of Experimental and Clinical Medicine, University of Catanzaro, Catanzaro, Italy  \n4AIL Sezione di Cosenza, Cosenza, Italy  \n5 Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy  \nCorrespondence  \nMassimo Gentile, Unit of Hematology, Department of Onco-Hematology, AO of Cosenza, viale della Repubblica snc, Cosenza 87100, Italy. [Email:](Email: massimo.gentile@unical.it)[ massimo.gentile@unical.it](Email: massimo.gentile@unical.it)  \nAbstract  \nBackground: Clonal haematopoiesis (CH) is an age-related condition increasingly recognised for its relevance in haematologic malignancies. In chronic lymphocytic leukaemia (CLL), its prevalence and clinical implications are gaining attention, particularly in the context of prolonged patient survival and the widespread adoption of targeted therapies. A comprehensive understanding of the biological and clinical significance of CH in CLL is therefore essential. Methods: This review synthesises current evidence on the biological basis, epidemiology and clinical impact of CH in CLL. Data from prospective clinical trials, real-world cohorts and translational studies were analysed to explore the associations between CH, genomic instability, immune dysregulation and inflammaging. Particular attention was given to the interaction between CH and contemporary therapeutic strategies, including Bruton tyrosine kinase (BTK) inhibitors and BCL2 inhibitors, and their potential influence on long-term outcomes.  \nResults: Available evidence indicates that CH is relatively frequent in patients with CLL and may contribute to disease biology through mechanisms involving genomic instability, chronic inflammation and immune system ","cbCaifDtf7pvIGjB","https://ap.wps.com/l/cbCaifDtf7pvIGjB","pdf",1231748,"English","# Background\n## Clonal haematopoiesis in CLL\n# Methods\n## Evidence synthesis and study sources\n## Translational links: CH, genomics and immunity\n## Interaction with targeted therapies\n# Results\n## Frequency and biological mechanisms in CLL\n## Clinical impact: prognosis, toxicities and risk\n## Therapy-related myeloid neoplasms and Richter transformation\n# Conclusions\n## Clinical management and future studies","[{\"question\":\"What is clonal haematopoiesis and why is it important in chronic lymphocytic leukaemia?\",\"answer\":\"Clonal haematopoiesis (CH) is an age-related condition that becomes increasingly recognized in haematologic malignancies. In CLL, CH prevalence and clinical implications are gaining attention because it may affect disease biology and patient outcomes.\"},{\"question\":\"How does CH relate to inflammaging and immune dysregulation in CLL?\",\"answer\":\"The review connects CH with genomic instability, chronic inflammation, and immune system alterations. CH is discussed as interacting with inflammaging and immune dysregulation, which can shape CLL progression and clinical risk.\"},{\"question\":\"What role might CH play in targeted therapy outcomes and adverse events?\",\"answer\":\"Available evidence suggests CH can influence prognosis and treatment-related toxicities, including cardiovascular risk. The review highlights that targeted therapies such as BTK and BCL2 inhibitors may interact differently with CH than chemoimmunotherapy, potentially modifying long-term outcomes.\"}]","Clonal haematopoiesis in chronic lymphocytic leukaemia - Biology, inflammaging and clinical implications in the era of targeted therapy | PDF",1790116956,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c46c05bcc3691ea489f155be5bd6737b.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e5967bb814933caabc90da4fcaf4114b.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7fd3d1de3260825d69a70cb66860b62a.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b028e11503b2590086cf5581f3c081a7.webp",980,1287]